Skip to main content
OpenTrials
Completed

NCT Number: NCT03796819

Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma

The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial. The investigators' multi-institutional retrospective study have showed an increasing adoption of LND among patients undergoing curative resection for ICC during the last decade. The current prospective and randomized study based on a multi-institutional collaboration would investigate whether routine LND would benefit patients in short- and long-term survival remains.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China

About this study

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and its incidence is increasing worldwide.Resection of the primary ICC tumor site within the liver represents the best curative treatment option. However, the role of lymphadenectomy (LND) at the time of surgery remains controversial with some centers considering it standard while other surgeons perform LND only in select circumstances. The utilization of LND may not only vary among different institutions, but also by geographic region. Specifically, data from East and West centers have noted a variation in the utilization of LND ranging 27%-100%.While several case series from Asia have noted that most centers do not regularly perform LND,other data from the West suggest that LND may be becoming more routine. Despite the lack of consensus among surgeons, the American Joint Committee on Cancer (AJCC) Staging manual recommends that the nodal basin be staged. Disease-specific staging for ICC was first introduced in the 7th edition of the AJCC staging manual published in 2010. The newly updated 8th edition of the AJCC staging system now recommends that 6 lymph nodes be evaluated to stage a patient with ICC.

The previous multi-institutional retrospective study from the investigators have showed an increasing adoption of LND among patients undergoing curative resection for ICC during the last decade. The current prospective and randomized study based on a multi-institutional collaboration would investigate whether routine LND would benefit patients in short- and long-term survival remains.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with intrahepatic cholangiocarcinoma by imaging or biopsy
  • The tumor is limited in the liver with no distant metastasis, and the primary disease is resectable
  • Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found no nodal swelling or enlargement

Exclusion criteria

  • The primary disease is unresectable with or without distant metastasis
  • The liver function or general condition of patients does not permit surgery
  • Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found obvious nodal swelling or enlargement, which indicates lymphadenectomy should be performed
  • Patients aged below 18 or older than 65 would be excluded
  • Pregnant women would not be enrolled

Treatment and study plan

Lymphadenectomy

Procedure

Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection

Primary outcomes

  1. 1-year recurrence rate

    Time frame: 1 year after surgery (up to 1 year)

    compare the 1-year recurrence rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy

  2. 3-year recurrence rate

    Time frame: 3 years after surgery (up to 3 years)

    compare the 3-year recurrence rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy

Secondary outcomes

  1. Postoperative morbidity

    Time frame: From the date of surgery to stitches off (up to 1 month)

    investigate the postoperative morbidity, such as hepatic failure, postoperative bleeding, superficial and deep site infection between lymphadenectomy and no lymphadenectomy groups

  2. 1-year overall survival

    Time frame: 1 year after surgery (up to 1 year)

    compare the 1-year overall survival rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy

  3. 3-year overall survival

    Time frame: 3 years after surgery (up to 3 years)

    compare the 3-year overall survival rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University

Other

Collaborators

  • Binzhou Medical University
  • Nanchang University
  • Ningxia Medical University
  • Shaanxi Provincial People's Hospital
  • Shaanxi University of Chinese Medicine
  • The Third Affiliated Hospital of Beijing University

Registry information

Official study title

Impact of Routine Lymphadenectomy on Prognosis of Patients Undergoing Curative Resection for Intrahepatic Cholangiocarcinoma

Acronym: LND for ICC

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jan 8, 2019
Registry last updated
Dec 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.